公司已经有多年没有收益, 并且在等待2026年FDA对两种药物的决定. Protagonist Therapeutics missed earnings, has cash for years, and awaits 2026 FDA decisions on two drugs.

主角治疗公司报告了2025年第四季度的业绩, 缺失了每股0.69美元的损失. Protagonist Therapeutics reported fourth-quarter 2025 results, missing earnings estimates with a loss of $0.69 per share. 该公司有6.46亿美元的现金,通过至少2028年为业务提供资金。 The company has $646 million in cash, funding operations through at least 2028. 该公司向FDA提交了rusfertide的NDA,美国可能会批准并于2026年推出,并计划在2026年第二季度退出与Takeda的利分享协议. It submitted an NDA for rusfertide to the FDA, with potential U.S. approval and launch in 2026, and plans to opt out of its profit-sharing deal with Takeda in Q2 2026. 预计2026年将对icotrokinra做出监管决定,并有可能在当年推出商用药物. A regulatory decision on icotrokinra is expected in 2026, with potential commercial launch that year. 该公司扩大了其临床前管道,有肥胖症和新陈代谢疾病的新候选者。 The company expanded its pre-clinical pipeline with new candidates for obesity and metabolic diseases. 由于里程碑付款减少,2025年许可证和协作收入大幅下降。 License and collaboration revenue dropped significantly in 2025 due to lower milestone payments.